Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. (NASDAQ: LUCD) is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. News about Lucid centers on its efforts to detect esophageal precancer in patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, using its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
On this page, readers can follow Lucid’s announcements on business updates, financial results, capital-raising activities, and clinical data related to EsoGuard and EsoCheck. Company press releases have highlighted quarterly financial results, the number of EsoGuard tests processed, and revenues associated with those tests, reflecting the commercial adoption of its esophageal precancer detection tools.
Lucid’s news flow also includes developments in reimbursement and coverage, such as Medicare Local Coverage Determination (LCD) processes and Contractor Advisory Committee (CAC) meetings where medical experts have discussed coverage for EsoGuard. The company issues updates on these milestones because they are important for expanding patient access and insurance coverage for its tests.
In addition, Lucid regularly announces participation in investor and industry conferences, business update webcasts, and leadership appointments related to market access and government affairs. Clinical and real-world data updates, including large analyses of EsoGuard and EsoCheck performance in routine practice, are another key component of its news, providing insight into safety, tolerability, technical success, and use in at-risk GERD populations.
Investors and observers can use this news page to track Lucid’s progress as a commercial-stage diagnostics company focused on early detection of esophageal precancer, along with its financial disclosures and strategic communications.
PAVmed (NASDAQ: PAVM) will implement a 1-for-30 reverse stock split of its common stock effective January 2, 2026 at 12:01 a.m. ET, with shares trading on a split-adjusted basis at the market open that day. The reverse split is intended to bring the company into compliance with Nasdaq's $1.00 minimum bid requirement.
The board approved the 1-for-30 ratio on December 8, 2025 following shareholder approval at a December 5, 2025 special meeting. As effective, authorized common shares will be reduced from 250,000,000 to 25,000,000. Equity awards, outstanding options, convertible securities, and employee purchase plan shares will be proportionately adjusted. No fractional shares will be issued; fractional holdings will be rounded up to the nearest whole share. New CUSIP: 70387R502.
Lucid Diagnostics (Nasdaq: LUCD) reported real-world data from an 18-month retrospective analysis of 11,991 at-risk patients who underwent EsoCheck cell collection and EsoGuard DNA testing between January 2023 and June 2024.
Key findings: 95% technical success, 95% of collections completed in under two minutes, and no serious adverse events. Authors concluded the results show safety, tolerability, scalability, and appropriate physician use consistent with prior studies.
Lucid Diagnostics (Nasdaq: LUCD) was named the winner in its company size category in the GenomeWeb 2025 Best Places to Work program on November 20, 2025.
The award recognizes top workplaces across diagnostics and precision medicine for transparent communication, an inclusive environment, professional development, and collaborative culture. Lucid is described as a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM). Company leadership credited employees for the recognition and emphasized a focus on patients, culture, scientific rigor, and long-term commercial success.
Lucid Diagnostics (Nasdaq: LUCD) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 in New York City.
Dennis McGrath, Lucid's Chief Financial Officer, will be available for one-on-one investor meetings; meetings must be scheduled through a Canaccord Genuity representative.
PAVmed (NASDAQ: PAVM) and subsidiaries Lucid Diagnostics (NASDAQ: LUCD) and Veris Health provided a business update and reported 3Q25 results on November 13, 2025. Key operating items: Lucid recognized $1.2M of EsoGuard revenue and processed 2,841 tests, and a Medicare Contractor Advisory Committee meeting showed unanimous expert support for Medicare coverage. Lucid completed an underwritten offering netting approximately $27.0M. Veris launched commercial deployment with OSU James and relaunched development of an implantable physiological monitor ahead of a planned 2026 510(k) submission. Financials: consolidated revenue was $5K for the quarter, GAAP net loss attributable to common stockholders was approximately $6.3M (loss per diluted share $(0.29)), non-GAAP adjusted loss was approximately $0.4M, and cash and cash equivalents totaled $3.1M.
Lucid Diagnostics (Nasdaq: LUCD) reported 3Q25 EsoGuard revenue of $1.2M from 2,841 tests processed, GAAP net loss of $10.4M (GAAP EPS $(0.10)), and non-GAAP adjusted loss of $10.3M ($(0.10) per share).
The company completed a public offering netting $27.0M, ended 3Q25 with $47.3M cash proforma, and said this extends runway through 2026 and past upcoming reimbursement milestones. A MolDx CAC meeting produced a unanimous expert consensus supporting Medicare coverage for EsoGuard, a key step in LCD reconsideration.
PAVmed (NASDAQ: LUCD) will host a business update conference call and webcast on November 13, 2025 at 8:30 AM ET. The call will feature Lishan Aklog, M.D., chairman and CEO, providing an overview of operations and growth strategy, and Dennis McGrath, president and CFO, discussing the company’s third quarter 2025 financial results.
The live webcast will be available in the investor relations section of pavmed.com. U.S. callers can join by dialing 1-800-836-8184; international listeners can dial 1-646-357-8785 and should request the conference name "PAVmed Business Update." A replay will be available on the investor relations website for 30 days after the call.
Lucid Diagnostics (Nasdaq: LUCD) will hold a business update conference call and webcast on Wednesday, November 12, 2025 at 8:30 AM ET. Management will include Lishan Aklog, M.D., chairman and CEO, who will provide a business update and growth strategy overview, and Dennis McGrath, CFO, who will discuss third quarter 2025 financial results. The webcast will be available in the investor relations section at luciddx.com. U.S. dial-in is 1-800-836-8184; international dial-in is 1-646-357-8785; ask the operator for the conference call name "Lucid Diagnostics Business Update" to join. A replay will be available for 30 days on the investor relations site.
Lucid Diagnostics (Nasdaq: LUCD) will participate in the 2025 Maxim Growth Summit in New York City on October 22-23, 2025.
Dennis McGrath, Lucid's Chief Financial Officer, will hold one-on-one investor meetings during the conference; investors should contact their Maxim representative to schedule meetings. Registration and event details are available through the Maxim Growth Summit event page.
Lucid Diagnostics (Nasdaq: LUCD) has appointed Danielle Scelfo as Senior Vice President of Market Access & Government Affairs. Scelfo, a veteran with over 25 years of experience in healthcare policy and market access, will focus on expanding insurance coverage and patient access for the company's EsoGuard® Esophageal DNA Test.
The appointment comes at a crucial time following a positive MolDX CAC meeting that suggests Medicare coverage is approaching. Scelfo's previous experience includes leadership roles at ClearNote Health, CareDx, Hologic, and other prominent healthcare companies. She will leverage her expertise to strengthen Lucid's market access infrastructure and accelerate commercial coverage expansion.
FAQ
What is the current stock price of Lucid Diagnostics (LUCD)?
What is the market cap of Lucid Diagnostics (LUCD)?
